Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
In this study, the investigators are looking at how people make decisions about
reward-related items, both monetary and food related after taking either the dopamine agonist
bromocriptine or the COMT inhibitor tolcapone, in healthy control subjects. Subjects will
fill self-report questionnaires and undergo an MRI scan.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Berkeley University of California, San Francisco
Collaborators:
University of California, Berkeley University of California, San Francisco